Esperion acquires Corstasis Therapeutics

Esperion Therapeutics has acquired Corstasis Therapeutics, enhancing its cardiovascular treatment portfolio. This transaction, while undisclosed in full value, involved an upfront cash payment of $75 million and potential milestone and royalty payments that could reach up to an additional $180 million. The deal, originally announced on March 2, 2026, is still pending final regulatory approvals.

Esperion, known for its focus on lipid management therapies, aims to leverage Corstasis's expertise and pipeline in heart failure treatments. The acquisition aligns with Esperion's strategy to broaden its cardiovascular offerings and potentially address unmet needs within this medical segment. Corstasis, headquartered in Henderson, Nevada, is recognized for its novel therapeutic approaches within the biopharmaceutical sphere.

The move positions Esperion to better compete in the crowded field of cardiovascular drug development, where large-scale pharmaceutical companies dominate. By acquiring Corstasis, Esperion can integrate innovative therapies that might enhance its competitive edge against rivals focused on similar chronic conditions.

Looking ahead, the completion of this acquisition depends on regulatory clearances. Once finalized, Esperion aims to expedite the development of Corstasis's products, seeking market entry swift enough to capitalize on growth opportunities in the cardiovascular therapeutics sector.